Viking Therapeutics' VK2735 Shows Weight Loss Success in Trial

Viking Therapeutics announced promising clinical trial results for its experimental weight-loss drug VK2735, a dual GLP-1/GIP receptor agonist that helped patients maintain significant weight reduction — including among those receiving injections just once a month. The news sent Viking's stock sharply higher as investors weighed the drug's competitive potential in a rapidly expanding obesity-treatment market.

VK2735 is designed to target the same hormonal pathways as Eli Lilly's blockbuster obesity drug Zepbound, putting Viking on a potential collision course with one of the sector's most dominant players. The ability to achieve results with monthly rather than weekly dosing could become a meaningful differentiator for patients and prescribers seeking greater convenience.

Read more JPMorgan Admits Oil Price Outlook Uncertain Amid Iran Tensions →

The GLP-1 drug space has emerged as one of the most fiercely contested battlegrounds in the pharmaceutical industry, with billions of dollars and millions of patients at stake. Clinical data showing sustained weight loss maintenance — not just initial reduction — addresses a long-standing challenge in obesity medicine, where patients frequently regain weight after stopping treatment.

Viking's trial results add fresh momentum to the company's efforts to carve out a credible position against deep-pocketed rivals. If VK2735 advances through late-stage development and earns regulatory approval, it could offer patients a new option while intensifying pricing and access competition across the obesity-drug landscape. Analysts will be watching closely for additional data on safety, tolerability, and how monthly dosing compares head-to-head with weekly alternatives.

Continue reading at MarketWatch.com